智通财经APP讯，绿竹生物-B(02480)公布，于美利坚合众国进行的 LZ901的I期临床试验已于2025年9月成功完成。根据该临床试验结果，LZ901疫苗高剂量组和低剂量组较安慰剂组而言，均表现出良好的安全性和免疫原性，为后续临床研究奠定了基础。
根据于美国进行的LZ901的I期临床试验结果，LZ901疫苗高剂量组和低剂量组较安慰剂组而言，均表现出良好的安全性和免疫原性。本次临床试验主要研究目标为验证疫苗的安全性，其中仅LZ901疫苗低剂量组出现与疫苗相关的轻度不良反应(4.35%)，LZ901疫苗高剂量组和安慰剂组均未出现与疫苗相关的不良反应。
LZ901是该集团自主开发的在研重组带状疱疹疫苗，并且是集团的核心产品，旨在预防年龄为40岁及以上成人带状疱疹及带状疱疹引致的相关并发症的发生(包括带状疱疹后遗神经痛)。LZ901于中华人民共和国的III期临床试验已达到临床预设目标，并取得符合预期的临床结果。截至本公告日期，LZ901的生物制品许可申请已获中国国家药品监督管理局受理，目前正在接受评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.